Inhibitor Therapeutics, Inc. (INTI)
Inhibitor Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Tampa, FL, US. The stock last traded at $0.08, up 9.33% on the session, giving a market capitalisation of $14.2M. On trailing twelve-month figures it carries a trailing P/E of -4.23, a net margin of 0.0%. Its beta of -0.71 implies it has historically moved less than the broad market.
Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions. A primary focus of their work involves advancing SUBA-Itraconazole, an oral variant of the drug itraconazole, for therapeutic applications in prostate and lung cancers. Furthermore, Inhibitor Therapeutics, Inc. has successfully completed a positive Phase 2b clinical trial for SUBA-Itraconazole in the management of basal cell carcinoma nevus syndrome. The organization was previously known as HedgePath Pharmaceuticals, Inc. until its name was officially changed in August 2019.
Inhibitor Therapeutics, Inc. is most often compared with the following Healthcare names: